期刊文献+

HA+马利兰/HA方案初治慢性粒细胞白血病疗效观察 被引量:5

HA Plus Myleran or HA Protocol Use for Initially Treated Chronic Myelogenous Leukemia
暂未订购
导出
摘要 12例初诊的慢性粒细胞白血病(CML)接受HA+马利兰/HA方案化疗.三尖杉酯硷 2~3mg/d,阿糖胞苷100~200ng/d,7~10天为1疗程.7例在停HA后即连用马利兰4~8mg/d×5~8天.1疗程未达CR者间隔2~3周开始第2疗程直至CR.结果;1疗程CR率66.6%,有效率100%;2疗程CR率100%;达CR中位时间30天.其中2例ph_1;阳性率治疗前后对比下降平均为48.6%.提示:HA+马利兰/HA方案缓解率及有效率明显高于单一马利兰;显效快,达CR迅速,作用轻.HA+马利兰较HA能加速CML获CR.对慢性期CML细胞遗传学有较好改善. From 1992 to 1994, 12 Cases of initially diagnosed chronic myelogenous leukemia were treated with HA (Homoharring tonine and Ara-C) or HA plus myleran regimen. All cases were response and 8 cases (66. 6%) reached complete remission (CR) after first course. 12 cases (100%) achieved CR after two courses. From treatment beginning to CR, there were median duration of 30 days (range 20-58). Ph1-Positive rates were reduced to the mean of 48. 6% at two cases. No severe toxicity was found. It is suggested that HA plus myleran or HA protocol have effect on initially treated chronic myelogenous leukemia.
出处 《临床血液学杂志》 CAS 1996年第1期13-15,共3页 Journal of Clinical Hematology
关键词 白血病 慢性粒细胞 HA方案 马利兰 药物疗法 Chronic myelogenous lenkemia Chemotherapy HA protocol mylelan
  • 相关文献

参考文献3

共引文献3

同被引文献10

引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部